Neurology 2014-05-06

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Peter A Lewitt, M Maral Mouradian

Index: Neurology 82(18) , 1574-5, (2014)

Full Text: HTML

Abstract

After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements. Whether disabling or minor, levodopa-induced dyskinesia (LID) constitutes an undesirable outcome calling for better treatment strategies. Options for managing LID include delaying its onset by combining a dopaminergic agonist with levodopa from the start(1) or symptomatic control using amantadine. However, fundamental questions about LID remain: by what mechanisms does it develop, and why don't all patients go on to experience LID after sustained levodopa exposure?

Related Compounds

  • 2-Deoxy-2-fluoro-...
  • Adamantan-1-amine
  • 1-Adamantanamine h...

Related Articles:

18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial.

2014-02-22

[Lancet 383(9918) , 705-13, (2014)]

11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.

2014-05-01

[J. Nucl. Med. 55(5) , 749-52, (2014)]

PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis.

2015-01-01

[J. Nucl. Med. 56(1) , 127-32, (2015)]

The [18F]FDG μPET readout of a brain activation model to evaluate the metabotropic glutamate receptor 2 positive allosteric modulator JNJ-42153605.

2014-08-01

[J. Pharmacol. Exp. Ther. 350(2) , 375-86, (2014)]

FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.

2013-06-01

[J. Pak. Med. Assoc. 63(6) , 725-30, (2013)]

More Articles...